Role and screening potential of let-7b-5p, miR-15a-5p, and miR-15b-5p in human prostate cancer

Author:

Sun Chen1,Li Xutai1,Lu Chong1,Wen Zhenyu1,Ge Zhenjian1,Chen Wenkang1,Li Yingqi1,Zhou Huimei1,Wu Yutong1,Lin Shengjie1,zhang Pengwu1,Wang Wuping1,Chen Siwei1,Li Hang1,Tao Lingzhi1,Wu Xionghui1,Lai Yongqing1

Affiliation:

1. Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, the fifth Clinical Medical College of Anhui Medical University

Abstract

Abstract

Prostate cancer is the fifth leading cause of male cancer mortality and poses a serious threat to men's health worldwide. PSA testing is widely used in prostate cancer screening, but its high false-positive rate leads to unnecessarily high subsequent testing costs, mental anguish and potential physical harm to patients. Therefore, there is an urgent need to develop a convenient, cost-effective and non-invasive diagnostic method to assist in reducing the false-positive rate of PSA screening. The aim of this study was to evaluate the diagnostic value of serum MicroRNA expression in patients with prostate cancer. We selected 10 miRNAs in the literature that were associated with prostate cancer. Afterwards, we measured the expression levels of these miRNAs in serum of 112 prostate cancer patients and healthy controls through a training phase and a validation phase. By plotting receiver operating characteristic curve, the miRNAs with the highest diagnosis value were chosen. Then, a set of miRNAs with the top diagnostic value was identified using stepwise logistic regression. The findings showed that 5 kinds of miRNAs (let-7b-5p, miR-15a-5p, miR-133a-3p, miR-15b-5p, miR-144-3p) were abnormally expressed in the serum of prostate cancer patients. The diagnostic panel constructed with these 3 miRNAs including let-7b-5p, miR-15a-5p miR-15b-5p and which have high specificity and sensitivity in detecting prostate cancer (area under the curve (AUC) = 0.899). Our study illustrates the potential of a three-microRNA panel in the diagnosis of prostate cancer, which can help in the early detection of prostate cancer and may even assist in reducing the false-positive rate of PSA screening.

Publisher

Springer Science and Business Media LLC

Reference46 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3